Antimicrobial resistance profiles of Campylobacter jejuni and Salmonella spp. isolated from enteritis patients in Japan
Understanding the antimicrobial resistance of Campylobacter jejuni and Salmonella spp. isolated from patients with enteritis will aid in therapeutic decision-making. This study aimed to characterize C. jejuni and Salmonella spp. isolates from patients with enteritis. For C. jejuni, the resistance ra...
Gespeichert in:
| Veröffentlicht in: | Journal of Veterinary Medical Science 2023, pp.22-0424 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 470 |
|---|---|
| container_issue | 4 |
| container_start_page | 22-0424 |
| container_title | Journal of Veterinary Medical Science |
| container_volume | 85 |
| creator | SASAKI, Yoshimasa IKEDA, Tetsuya YONEMITSU, Kenzo KURODA, Makoto OGAWA, Miho SAKATA, Ryuji UEMA, Masashi MOMOSE, Yoshika OHYA, Kenji WATANABE, Maiko HARA-KUDO, Yukiko OKAMURA, Masashi ASAI, Tetsuo |
| description | Understanding the antimicrobial resistance of Campylobacter jejuni and Salmonella spp. isolated from patients with enteritis will aid in therapeutic decision-making. This study aimed to characterize C. jejuni and Salmonella spp. isolates from patients with enteritis. For C. jejuni, the resistance rates against ampicillin, tetracycline, and ciprofloxacin were 17.2%, 23.8%, and 46.4%, respectively. All the C. jejuni isolates were susceptible to erythromycin, which is recommended as a first-choice antimicrobial if Campylobacter enteritis is strongly suspected. C. jejuni was classified into 64 sequence types (STs), and the five major STs were ST22, ST354, ST21, ST918, and ST50. The ciprofloxacin-resistance rate of ST22 was 85.7%. For Salmonella, the resistance rates against ampicillin, cefotaxime, streptomycin, kanamycin, tetracycline, and nalidixic acid were 14.7%, 2.0%, 57.8%, 10.8%, 16.7%, and 11.8%, respectively. All the Salmonella spp. isolates were susceptible to ciprofloxacin. Therefore, fluoroquinolones are the recommended antimicrobials against Salmonella enteritis. S. Thompson, S. Enteritidis, and S. Schwarzengrund were the three most prevalent serotypes. The two cefotaxime-resistant isolates were serotyped as S. Typhimurium and were found to harbor blaCMY-2. The results of this study would help select antimicrobials for treating patients with Campylobacter and Salmonella enteritis. |
| doi_str_mv | 10.1292/jvms.22-0424 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10139799</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2813492473</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5424-7d74524795ff33fe7d64874de27d7330df4980b13921fd993d50ee168e16af6a3</originalsourceid><addsrcrecordid>eNpdkc1v1DAQxS0EotuFG2dkiQsHsvgrcXxC1QoKVSUOwNmaje3WUWIHO9mq_z1e7XYFHCx7ND8_zZuH0BtKNpQp9rHfj3nDWEUEE8_QinIhKym4eo5WRNGmkqwmF-gy554QRkWjXqIL3rSyrWu-Qg9XYfaj71LceRhwstnnGUJn8ZSi84PNODq8hXF6HOIOutkm3Nt-CR5DMPgHDGMMdhgA52naYJ_jALM12KU4YhsK7mef8QSzL1XGPuAbmCC8Qi8cDNm-Pt1r9OvL55_br9Xt9-tv26vbqquLn0oaKWompKqd49xZaRrRSmEsKx3OiXFCtWRHuWLUGaW4qYm1tGnLAdcAX6NPR91p2Y3WdGWIBIOekh8hPeoIXv_bCf5e38W9pqSIyqK4Ru9PCin-Xmye9ehzd7AcbFyyZrIVvBWtOKDv_kP7uKRQ_GnWlmBUccIL9eFIlaXnnKw7T0OJPkSqD5FqxvQh0oK__dvBGX7KsAA3R6Avyd3ZMwBp9t1gj2pg9uW_Jk-Pk_oZ6u4haRv4HzWyu1k</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2813492473</pqid></control><display><type>article</type><title>Antimicrobial resistance profiles of Campylobacter jejuni and Salmonella spp. isolated from enteritis patients in Japan</title><source>J-STAGE Free</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>SASAKI, Yoshimasa ; IKEDA, Tetsuya ; YONEMITSU, Kenzo ; KURODA, Makoto ; OGAWA, Miho ; SAKATA, Ryuji ; UEMA, Masashi ; MOMOSE, Yoshika ; OHYA, Kenji ; WATANABE, Maiko ; HARA-KUDO, Yukiko ; OKAMURA, Masashi ; ASAI, Tetsuo</creator><creatorcontrib>SASAKI, Yoshimasa ; IKEDA, Tetsuya ; YONEMITSU, Kenzo ; KURODA, Makoto ; OGAWA, Miho ; SAKATA, Ryuji ; UEMA, Masashi ; MOMOSE, Yoshika ; OHYA, Kenji ; WATANABE, Maiko ; HARA-KUDO, Yukiko ; OKAMURA, Masashi ; ASAI, Tetsuo</creatorcontrib><description>Understanding the antimicrobial resistance of Campylobacter jejuni and Salmonella spp. isolated from patients with enteritis will aid in therapeutic decision-making. This study aimed to characterize C. jejuni and Salmonella spp. isolates from patients with enteritis. For C. jejuni, the resistance rates against ampicillin, tetracycline, and ciprofloxacin were 17.2%, 23.8%, and 46.4%, respectively. All the C. jejuni isolates were susceptible to erythromycin, which is recommended as a first-choice antimicrobial if Campylobacter enteritis is strongly suspected. C. jejuni was classified into 64 sequence types (STs), and the five major STs were ST22, ST354, ST21, ST918, and ST50. The ciprofloxacin-resistance rate of ST22 was 85.7%. For Salmonella, the resistance rates against ampicillin, cefotaxime, streptomycin, kanamycin, tetracycline, and nalidixic acid were 14.7%, 2.0%, 57.8%, 10.8%, 16.7%, and 11.8%, respectively. All the Salmonella spp. isolates were susceptible to ciprofloxacin. Therefore, fluoroquinolones are the recommended antimicrobials against Salmonella enteritis. S. Thompson, S. Enteritidis, and S. Schwarzengrund were the three most prevalent serotypes. The two cefotaxime-resistant isolates were serotyped as S. Typhimurium and were found to harbor blaCMY-2. The results of this study would help select antimicrobials for treating patients with Campylobacter and Salmonella enteritis.</description><identifier>ISSN: 0916-7250</identifier><identifier>EISSN: 1347-7439</identifier><identifier>DOI: 10.1292/jvms.22-0424</identifier><identifier>PMID: 36878553</identifier><language>eng</language><publisher>Japan: JAPANESE SOCIETY OF VETERINARY SCIENCE</publisher><subject>Ampicillin ; Ampicillin - therapeutic use ; Animals ; Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Anti-Infective Agents - therapeutic use ; Antimicrobial agents ; Antimicrobial resistance ; Campylobacter ; Campylobacter Infections - drug therapy ; Campylobacter Infections - epidemiology ; Campylobacter Infections - veterinary ; Campylobacter jejuni ; Cefotaxime ; Cefotaxime - therapeutic use ; Ciprofloxacin ; Ciprofloxacin - pharmacology ; Decision making ; Drug resistance ; Drug Resistance, Bacterial ; Enteritis ; Enteritis - epidemiology ; Enteritis - veterinary ; Erythromycin ; Fluoroquinolones ; Japan - epidemiology ; Kanamycin ; Microbial Sensitivity Tests - veterinary ; Nalidixic acid ; Public Health ; Salmonella ; Serotypes ; Streptomycin ; Tetracycline - therapeutic use</subject><ispartof>Journal of Veterinary Medical Science, 2023, pp.22-0424</ispartof><rights>2023 by the Japanese Society of Veterinary Science</rights><rights>2023. This work is published under https://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 The Japanese Society of Veterinary Science 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5424-7d74524795ff33fe7d64874de27d7330df4980b13921fd993d50ee168e16af6a3</citedby><cites>FETCH-LOGICAL-c5424-7d74524795ff33fe7d64874de27d7330df4980b13921fd993d50ee168e16af6a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139799/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139799/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,1877,4010,27900,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36878553$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SASAKI, Yoshimasa</creatorcontrib><creatorcontrib>IKEDA, Tetsuya</creatorcontrib><creatorcontrib>YONEMITSU, Kenzo</creatorcontrib><creatorcontrib>KURODA, Makoto</creatorcontrib><creatorcontrib>OGAWA, Miho</creatorcontrib><creatorcontrib>SAKATA, Ryuji</creatorcontrib><creatorcontrib>UEMA, Masashi</creatorcontrib><creatorcontrib>MOMOSE, Yoshika</creatorcontrib><creatorcontrib>OHYA, Kenji</creatorcontrib><creatorcontrib>WATANABE, Maiko</creatorcontrib><creatorcontrib>HARA-KUDO, Yukiko</creatorcontrib><creatorcontrib>OKAMURA, Masashi</creatorcontrib><creatorcontrib>ASAI, Tetsuo</creatorcontrib><title>Antimicrobial resistance profiles of Campylobacter jejuni and Salmonella spp. isolated from enteritis patients in Japan</title><title>Journal of Veterinary Medical Science</title><addtitle>J. Vet. Med. Sci.</addtitle><description>Understanding the antimicrobial resistance of Campylobacter jejuni and Salmonella spp. isolated from patients with enteritis will aid in therapeutic decision-making. This study aimed to characterize C. jejuni and Salmonella spp. isolates from patients with enteritis. For C. jejuni, the resistance rates against ampicillin, tetracycline, and ciprofloxacin were 17.2%, 23.8%, and 46.4%, respectively. All the C. jejuni isolates were susceptible to erythromycin, which is recommended as a first-choice antimicrobial if Campylobacter enteritis is strongly suspected. C. jejuni was classified into 64 sequence types (STs), and the five major STs were ST22, ST354, ST21, ST918, and ST50. The ciprofloxacin-resistance rate of ST22 was 85.7%. For Salmonella, the resistance rates against ampicillin, cefotaxime, streptomycin, kanamycin, tetracycline, and nalidixic acid were 14.7%, 2.0%, 57.8%, 10.8%, 16.7%, and 11.8%, respectively. All the Salmonella spp. isolates were susceptible to ciprofloxacin. Therefore, fluoroquinolones are the recommended antimicrobials against Salmonella enteritis. S. Thompson, S. Enteritidis, and S. Schwarzengrund were the three most prevalent serotypes. The two cefotaxime-resistant isolates were serotyped as S. Typhimurium and were found to harbor blaCMY-2. The results of this study would help select antimicrobials for treating patients with Campylobacter and Salmonella enteritis.</description><subject>Ampicillin</subject><subject>Ampicillin - therapeutic use</subject><subject>Animals</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Anti-Infective Agents - therapeutic use</subject><subject>Antimicrobial agents</subject><subject>Antimicrobial resistance</subject><subject>Campylobacter</subject><subject>Campylobacter Infections - drug therapy</subject><subject>Campylobacter Infections - epidemiology</subject><subject>Campylobacter Infections - veterinary</subject><subject>Campylobacter jejuni</subject><subject>Cefotaxime</subject><subject>Cefotaxime - therapeutic use</subject><subject>Ciprofloxacin</subject><subject>Ciprofloxacin - pharmacology</subject><subject>Decision making</subject><subject>Drug resistance</subject><subject>Drug Resistance, Bacterial</subject><subject>Enteritis</subject><subject>Enteritis - epidemiology</subject><subject>Enteritis - veterinary</subject><subject>Erythromycin</subject><subject>Fluoroquinolones</subject><subject>Japan - epidemiology</subject><subject>Kanamycin</subject><subject>Microbial Sensitivity Tests - veterinary</subject><subject>Nalidixic acid</subject><subject>Public Health</subject><subject>Salmonella</subject><subject>Serotypes</subject><subject>Streptomycin</subject><subject>Tetracycline - therapeutic use</subject><issn>0916-7250</issn><issn>1347-7439</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkc1v1DAQxS0EotuFG2dkiQsHsvgrcXxC1QoKVSUOwNmaje3WUWIHO9mq_z1e7XYFHCx7ND8_zZuH0BtKNpQp9rHfj3nDWEUEE8_QinIhKym4eo5WRNGmkqwmF-gy554QRkWjXqIL3rSyrWu-Qg9XYfaj71LceRhwstnnGUJn8ZSi84PNODq8hXF6HOIOutkm3Nt-CR5DMPgHDGMMdhgA52naYJ_jALM12KU4YhsK7mef8QSzL1XGPuAbmCC8Qi8cDNm-Pt1r9OvL55_br9Xt9-tv26vbqquLn0oaKWompKqd49xZaRrRSmEsKx3OiXFCtWRHuWLUGaW4qYm1tGnLAdcAX6NPR91p2Y3WdGWIBIOekh8hPeoIXv_bCf5e38W9pqSIyqK4Ru9PCin-Xmye9ehzd7AcbFyyZrIVvBWtOKDv_kP7uKRQ_GnWlmBUccIL9eFIlaXnnKw7T0OJPkSqD5FqxvQh0oK__dvBGX7KsAA3R6Avyd3ZMwBp9t1gj2pg9uW_Jk-Pk_oZ6u4haRv4HzWyu1k</recordid><startdate>2023</startdate><enddate>2023</enddate><creator>SASAKI, Yoshimasa</creator><creator>IKEDA, Tetsuya</creator><creator>YONEMITSU, Kenzo</creator><creator>KURODA, Makoto</creator><creator>OGAWA, Miho</creator><creator>SAKATA, Ryuji</creator><creator>UEMA, Masashi</creator><creator>MOMOSE, Yoshika</creator><creator>OHYA, Kenji</creator><creator>WATANABE, Maiko</creator><creator>HARA-KUDO, Yukiko</creator><creator>OKAMURA, Masashi</creator><creator>ASAI, Tetsuo</creator><general>JAPANESE SOCIETY OF VETERINARY SCIENCE</general><general>Japan Science and Technology Agency</general><general>The Japanese Society of Veterinary Science</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QR</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2023</creationdate><title>Antimicrobial resistance profiles of Campylobacter jejuni and Salmonella spp. isolated from enteritis patients in Japan</title><author>SASAKI, Yoshimasa ; IKEDA, Tetsuya ; YONEMITSU, Kenzo ; KURODA, Makoto ; OGAWA, Miho ; SAKATA, Ryuji ; UEMA, Masashi ; MOMOSE, Yoshika ; OHYA, Kenji ; WATANABE, Maiko ; HARA-KUDO, Yukiko ; OKAMURA, Masashi ; ASAI, Tetsuo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5424-7d74524795ff33fe7d64874de27d7330df4980b13921fd993d50ee168e16af6a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Ampicillin</topic><topic>Ampicillin - therapeutic use</topic><topic>Animals</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Anti-Infective Agents - therapeutic use</topic><topic>Antimicrobial agents</topic><topic>Antimicrobial resistance</topic><topic>Campylobacter</topic><topic>Campylobacter Infections - drug therapy</topic><topic>Campylobacter Infections - epidemiology</topic><topic>Campylobacter Infections - veterinary</topic><topic>Campylobacter jejuni</topic><topic>Cefotaxime</topic><topic>Cefotaxime - therapeutic use</topic><topic>Ciprofloxacin</topic><topic>Ciprofloxacin - pharmacology</topic><topic>Decision making</topic><topic>Drug resistance</topic><topic>Drug Resistance, Bacterial</topic><topic>Enteritis</topic><topic>Enteritis - epidemiology</topic><topic>Enteritis - veterinary</topic><topic>Erythromycin</topic><topic>Fluoroquinolones</topic><topic>Japan - epidemiology</topic><topic>Kanamycin</topic><topic>Microbial Sensitivity Tests - veterinary</topic><topic>Nalidixic acid</topic><topic>Public Health</topic><topic>Salmonella</topic><topic>Serotypes</topic><topic>Streptomycin</topic><topic>Tetracycline - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SASAKI, Yoshimasa</creatorcontrib><creatorcontrib>IKEDA, Tetsuya</creatorcontrib><creatorcontrib>YONEMITSU, Kenzo</creatorcontrib><creatorcontrib>KURODA, Makoto</creatorcontrib><creatorcontrib>OGAWA, Miho</creatorcontrib><creatorcontrib>SAKATA, Ryuji</creatorcontrib><creatorcontrib>UEMA, Masashi</creatorcontrib><creatorcontrib>MOMOSE, Yoshika</creatorcontrib><creatorcontrib>OHYA, Kenji</creatorcontrib><creatorcontrib>WATANABE, Maiko</creatorcontrib><creatorcontrib>HARA-KUDO, Yukiko</creatorcontrib><creatorcontrib>OKAMURA, Masashi</creatorcontrib><creatorcontrib>ASAI, Tetsuo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Chemoreception Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Veterinary Medical Science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SASAKI, Yoshimasa</au><au>IKEDA, Tetsuya</au><au>YONEMITSU, Kenzo</au><au>KURODA, Makoto</au><au>OGAWA, Miho</au><au>SAKATA, Ryuji</au><au>UEMA, Masashi</au><au>MOMOSE, Yoshika</au><au>OHYA, Kenji</au><au>WATANABE, Maiko</au><au>HARA-KUDO, Yukiko</au><au>OKAMURA, Masashi</au><au>ASAI, Tetsuo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antimicrobial resistance profiles of Campylobacter jejuni and Salmonella spp. isolated from enteritis patients in Japan</atitle><jtitle>Journal of Veterinary Medical Science</jtitle><addtitle>J. Vet. Med. Sci.</addtitle><date>2023</date><risdate>2023</risdate><volume>85</volume><issue>4</issue><spage>22-0424</spage><epage>470</epage><pages>22-0424-470</pages><artnum>22-0424</artnum><issn>0916-7250</issn><eissn>1347-7439</eissn><abstract>Understanding the antimicrobial resistance of Campylobacter jejuni and Salmonella spp. isolated from patients with enteritis will aid in therapeutic decision-making. This study aimed to characterize C. jejuni and Salmonella spp. isolates from patients with enteritis. For C. jejuni, the resistance rates against ampicillin, tetracycline, and ciprofloxacin were 17.2%, 23.8%, and 46.4%, respectively. All the C. jejuni isolates were susceptible to erythromycin, which is recommended as a first-choice antimicrobial if Campylobacter enteritis is strongly suspected. C. jejuni was classified into 64 sequence types (STs), and the five major STs were ST22, ST354, ST21, ST918, and ST50. The ciprofloxacin-resistance rate of ST22 was 85.7%. For Salmonella, the resistance rates against ampicillin, cefotaxime, streptomycin, kanamycin, tetracycline, and nalidixic acid were 14.7%, 2.0%, 57.8%, 10.8%, 16.7%, and 11.8%, respectively. All the Salmonella spp. isolates were susceptible to ciprofloxacin. Therefore, fluoroquinolones are the recommended antimicrobials against Salmonella enteritis. S. Thompson, S. Enteritidis, and S. Schwarzengrund were the three most prevalent serotypes. The two cefotaxime-resistant isolates were serotyped as S. Typhimurium and were found to harbor blaCMY-2. The results of this study would help select antimicrobials for treating patients with Campylobacter and Salmonella enteritis.</abstract><cop>Japan</cop><pub>JAPANESE SOCIETY OF VETERINARY SCIENCE</pub><pmid>36878553</pmid><doi>10.1292/jvms.22-0424</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0916-7250 |
| ispartof | Journal of Veterinary Medical Science, 2023, pp.22-0424 |
| issn | 0916-7250 1347-7439 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10139799 |
| source | J-STAGE Free; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Ampicillin Ampicillin - therapeutic use Animals Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Anti-Infective Agents - therapeutic use Antimicrobial agents Antimicrobial resistance Campylobacter Campylobacter Infections - drug therapy Campylobacter Infections - epidemiology Campylobacter Infections - veterinary Campylobacter jejuni Cefotaxime Cefotaxime - therapeutic use Ciprofloxacin Ciprofloxacin - pharmacology Decision making Drug resistance Drug Resistance, Bacterial Enteritis Enteritis - epidemiology Enteritis - veterinary Erythromycin Fluoroquinolones Japan - epidemiology Kanamycin Microbial Sensitivity Tests - veterinary Nalidixic acid Public Health Salmonella Serotypes Streptomycin Tetracycline - therapeutic use |
| title | Antimicrobial resistance profiles of Campylobacter jejuni and Salmonella spp. isolated from enteritis patients in Japan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T13%3A22%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antimicrobial%20resistance%20profiles%20of%20Campylobacter%20jejuni%20and%20Salmonella%20spp.%20isolated%20from%20enteritis%20patients%20in%20Japan&rft.jtitle=Journal%20of%20Veterinary%20Medical%20Science&rft.au=SASAKI,%20Yoshimasa&rft.date=2023&rft.volume=85&rft.issue=4&rft.spage=22-0424&rft.epage=470&rft.pages=22-0424-470&rft.artnum=22-0424&rft.issn=0916-7250&rft.eissn=1347-7439&rft_id=info:doi/10.1292/jvms.22-0424&rft_dat=%3Cproquest_pubme%3E2813492473%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2813492473&rft_id=info:pmid/36878553&rfr_iscdi=true |